Verition Fund Management LLC Has $9.42 Million Holdings in Agilent Technologies, Inc. (NYSE:A)

Verition Fund Management LLC raised its holdings in shares of Agilent Technologies, Inc. (NYSE:AFree Report) by 487.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 67,725 shares of the medical research company’s stock after buying an additional 56,190 shares during the quarter. Verition Fund Management LLC’s holdings in Agilent Technologies were worth $9,416,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Agilent Technologies by 3.2% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,421 shares of the medical research company’s stock worth $337,000 after buying an additional 75 shares during the last quarter. Carmel Capital Partners LLC increased its position in shares of Agilent Technologies by 1.2% during the fourth quarter. Carmel Capital Partners LLC now owns 6,709 shares of the medical research company’s stock valued at $933,000 after purchasing an additional 78 shares during the period. Monumental Financial Group Inc. increased its position in shares of Agilent Technologies by 0.9% during the fourth quarter. Monumental Financial Group Inc. now owns 9,493 shares of the medical research company’s stock valued at $1,320,000 after purchasing an additional 89 shares during the period. Kepos Capital LP increased its position in shares of Agilent Technologies by 3.5% during the third quarter. Kepos Capital LP now owns 2,775 shares of the medical research company’s stock valued at $310,000 after purchasing an additional 93 shares during the period. Finally, Rosenberg Matthew Hamilton increased its position in shares of Agilent Technologies by 51.1% during the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 96 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on A. Oppenheimer upped their price target on Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Jefferies Financial Group reiterated a “hold” rating and issued a $135.00 price target (down from $152.00) on shares of Agilent Technologies in a research report on Monday, June 3rd. JPMorgan Chase & Co. reduced their price objective on Agilent Technologies from $165.00 to $155.00 and set an “overweight” rating on the stock in a research note on Thursday, May 30th. Stifel Nicolaus reduced their price objective on Agilent Technologies from $163.00 to $151.00 and set a “buy” rating on the stock in a research note on Thursday, May 30th. Finally, Evercore ISI reduced their price objective on Agilent Technologies from $145.00 to $126.00 and set an “in-line” rating on the stock in a research note on Thursday, May 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $136.50.

Check Out Our Latest Stock Analysis on Agilent Technologies

Agilent Technologies Trading Up 0.1 %

NYSE:A opened at $133.07 on Tuesday. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $155.35. The business’s 50-day moving average price is $141.86 and its two-hundred day moving average price is $138.06. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $38.82 billion, a price-to-earnings ratio of 31.46, a PEG ratio of 4.51 and a beta of 1.07.

Agilent Technologies (NYSE:AGet Free Report) last announced its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.58 billion. During the same period in the prior year, the company earned $1.27 earnings per share. The company’s revenue for the quarter was down 8.4% compared to the same quarter last year. On average, equities analysts expect that Agilent Technologies, Inc. will post 5.25 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be issued a dividend of $0.236 per share. The ex-dividend date of this dividend is Tuesday, July 2nd. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.71%. Agilent Technologies’s payout ratio is presently 22.22%.

Insider Buying and Selling

In other Agilent Technologies news, SVP Philip Binns sold 2,827 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the transaction, the senior vice president now directly owns 9,997 shares in the company, valued at $1,474,957.38. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the sale, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at $3,274,050. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Philip Binns sold 2,827 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the sale, the senior vice president now directly owns 9,997 shares of the company’s stock, valued at $1,474,957.38. The disclosure for this sale can be found here.

Agilent Technologies Company Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Stories

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.